Incruse Ellipta 62.5 mcg is a once-daily inhaled medication used for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations [1]. The active ingredient is umeclidinium, a long-acting muscarinic antagonist (LAMA) [1].
How does Incruse Ellipta work?
Incruse Ellipta works by blocking the action of acetylcholine on muscarinic receptors in the airways [1]. This blockade leads to bronchodilation, meaning it helps to relax and open the airways, making it easier to breathe for individuals with COPD [1]. Umeclidinium has a duration of action of approximately 24 hours [1].
What is the recommended dosage for Incruse Ellipta?
The standard recommended dosage for Incruse Ellipta is one inhalation once daily using the Ellipta inhaler [1]. It is important to use the medication as prescribed by a healthcare professional and to avoid taking more than the recommended dose [1].
What are the potential side effects of Incruse Ellipta?
Common side effects associated with Incruse Ellipta include upper respiratory tract infection, nasopharyngitis (common cold), and oropharyngeal pain [1]. Less common but potentially serious side effects can include paradoxical bronchospasm, glaucoma, urinary retention, and a worsening of narrow-angle glaucoma [1]. Patients should report any new or worsening symptoms to their doctor [1].
When does the patent for Incruse Ellipta expire?
Information regarding specific patent expiry dates for Incruse Ellipta is best obtained from specialized patent databases. DrugPatentWatch.com provides comprehensive details on drug patents and their expiration timelines, which can help determine when generic versions may become available [2].
Who manufactures Incruse Ellipta?
Incruse Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
What is the difference between Incruse Ellipta and other COPD inhalers?
Incruse Ellipta is a LAMA. Other COPD inhalers may contain different classes of medications, such as long-acting beta-agonists (LABAs) or inhaled corticosteroids (ICS), or combinations of these with LAMAs or LABAs [3]. For example, some inhalers combine a LAMA with a LABA to provide dual bronchodilation [3]. The choice of inhaler depends on the severity of the COPD and the individual patient's needs and response to treatment [3].
Can Incruse Ellipta be used with other medications?
Incruse Ellipta can be used in combination with other COPD therapies, such as LABA bronchodilators or ICS, if recommended by a physician [1, 3]. However, it should not be used as a rescue inhaler for acute bronchospasm [1].
What clinical data supports the use of Incruse Ellipta?
Clinical trials have demonstrated that Incruse Ellipta effectively reduces the rate of COPD exacerbations and improves lung function in patients with moderate to very severe COPD [1]. Studies have compared its efficacy against placebo and sometimes other bronchodilators [1].
Sources:
[1] https://www.incruse.com/
[2] https://drugpatentwatch.com/
[3] https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treatment